<p>CenterBook Partners LP 在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Humacyte, Inc. (NASDAQ:HUMA - 免费报告) 的持股比例削减了 91.7%。该机构投资者在此期间出售了 3,146,628 股后，持有该公司 283,627 股股票。CenterBook Partners LP 在最近的报告期末持有的 Humacyte 股票约占 0.18%，价值 494,000 美元。</p>
<p>其他一些机构投资者和对冲基金最近也买卖了 HUMA 的股票。CWM LLC 在第二季度将其在 Humacyte 的持股比例提高了 29,921.4%。CWM LLC 现在持有 43,531 股该公司的股票，价值 91,000 美元，此前在此期间又购买了 43,386 股。Savant Capital LLC 在第二季度获得了 Humacyte 的新头寸，价值 122,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度购买了 Humacyte 的新头寸，价值约 30,000 美元。SBI Securities Co. Ltd. 在第二季度将其在 Humacyte 的持股比例提高了 6,305.4%。SBI Securities Co. Ltd. 现在持有 68,218 股该公司的股票，价值 143,000 美元，此前在上个季度又收购了 67,153 股。最后，Letko Brosseau &amp; Associates Inc. 在第二季度将其在 Humacyte 的持股比例提高了 85.3%。Letko Brosseau &amp; Associates Inc. 现在持有 45,950 股该公司的股票，价值 96,000 美元，此前在上个季度又收购了 21,150 股。对冲基金和其他机构投资者持有该公司 44.71% 的股票。</p>
<h2>Humacyte 股票下跌 1.7%</h2>
<p>NASDAQ:HUMA 的股票在周五开盘时为 1.13 美元。该公司的 50 日移动平均线为 1.06 美元，200 日移动平均线为 1.39 美元。该公司的债务与股本比率为 2.97，速动比率为 0.90，流动比率为 1.62。Humacyte, Inc. 的 1 年最低价为 0.88 美元，1 年最高价为 3.94 美元。该股票的市值为 2.1162 亿美元，市盈率为 -4.91，贝塔值为 1.93。</p>
<h2>分析师评级调整</h2>
<p>HUMA 曾受到多份分析师报告的关注。D. Boral Capital 在周四的研究报告中重申了对 Humacyte 的 &#34;买入&#34; 评级，并设定了 25.00 美元的目标价。Benchmark 在 1 月 21 日的研究报告中将 Humacyte 的目标价从 11.00 美元下调至 10.00 美元，并对该公司设定了 &#34;买入&#34; 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Humacyte 的 &#34;卖出 (d-)&#34; 评级。Wall Street Zen 在 12 月 21 日的报告中将 Humacyte 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。最后，BTIG Research 在 2 月 9 日的研究报告中重申了对 Humacyte 的 &#34;买入&#34; 评级，并设定了 6.00 美元的目标价。七位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 8.14 美元。</p>
<p><strong>阅读我们关于 HUMA 的最新报告</strong></p>
<h2>Humacyte 公司简介</h2>
<p>(免费报告)</p>
<p>Humacyte, Inc 是一家临床阶段的生物技术公司，专注于开发和制造现成的再生人类无细胞血管 (HAVs)，旨在满足关键的血管通路需求。该公司的专有血管由人类供体细胞工程化而成，然后去细胞化，以创建一种能够与患者自身组织整合的生物相容性支架。Humacyte 的主要业务活动包括 HAVs 的工艺开发、大规模生产和临床评估，适用于终末期肾病、外周动脉疾病和其他血管修复应用。</p>
<p>该公司的主要产品候选者 HAV 已通过多项临床试验，针对血液透析患者的动静脉通路，显示出耐用性、降低感染率和与重复穿刺的兼容性。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Humacyte</li>
<li>~$1.5T SpaceX IPO：首次公开募股机会</li>
<li>黄金 $5,000:2026 年黄金与白银峰会将于 3 月 4 日直播</li>
<li>家族信托如何帮助保护您的财富</li>
<li>这让我感到愤怒</li>
<li>Elon Musk：这可能将 $100 变成 $100,000</li>
</ul>
<p><strong>想看看其他对冲基金持有的 HUMA 吗？</strong> 访问 HoldingsChannel.com 获取 Humacyte, Inc. (NASDAQ:HUMA - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Humacyte 吗？</h2>
<p>在考虑 Humacyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Humacyte 并不在名单上。</p>
<p>虽然 Humacyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

IBBQ

动态生物技术与基因组 ETF - Invesco

HUMA

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>CenterBook Partners LP 在第三季度大幅减少了对 Humacyte, Inc. (NASDAQ:HUMA) 的持股，减少幅度达到 91.7%，目前持有 283,627 股，之前出售了 3,146,628 股。其他机构投资者也调整了他们的持仓。Humacyte 的股票目前下跌 1.7%，交易价格为 1.13 美元，市值为 2.1162 亿美元。分析师的评级意见不一，普遍评级为 “适度买入”，目标价格为 8.14 美元。Humacyte 专注于开发用于血管通路需求的再生人类无细胞血管</p>

<p>CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 283,627 shares of the company's stock after selling 3,146,628 shares during the period. CenterBook Partners LP owned approximately 0.18% of Humacyte worth $494,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>CenterBook Partners LP 在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Humacyte, Inc. (NASDAQ:HUMA - 免费报告) 的持股比例削减了 91.7%。该机构投资者在此期间出售了 3,146,628 股后，持有该公司 283,627 股股票。CenterBook Partners LP 在最近的报告期末持有的 Humacyte 股票约占 0.18%，价值 494,000 美元。</p>
</div><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of HUMA. CWM LLC boosted its stake in shares of Humacyte by 29,921.4% in the second quarter. CWM LLC now owns 43,531 shares of the company's stock valued at $91,000 after purchasing an additional 43,386 shares during the period. Savant Capital LLC acquired a new position in Humacyte in the 2nd quarter worth $122,000. Vanguard Personalized Indexing Management LLC purchased a new position in Humacyte in the 2nd quarter valued at about $30,000. SBI Securities Co. Ltd. grew its stake in shares of Humacyte by 6,305.4% during the second quarter. SBI Securities Co. Ltd. now owns 68,218 shares of the company's stock valued at $143,000 after acquiring an additional 67,153 shares in the last quarter. Finally, Letko Brosseau &amp; Associates Inc. increased its position in shares of Humacyte by 85.3% during the second quarter. Letko Brosseau &amp; Associates Inc. now owns 45,950 shares of the company's stock worth $96,000 after acquiring an additional 21,150 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也买卖了 HUMA 的股票。CWM LLC 在第二季度将其在 Humacyte 的持股比例提高了 29,921.4%。CWM LLC 现在持有 43,531 股该公司的股票，价值 91,000 美元，此前在此期间又购买了 43,386 股。Savant Capital LLC 在第二季度获得了 Humacyte 的新头寸，价值 122,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度购买了 Humacyte 的新头寸，价值约 30,000 美元。SBI Securities Co. Ltd. 在第二季度将其在 Humacyte 的持股比例提高了 6,305.4%。SBI Securities Co. Ltd. 现在持有 68,218 股该公司的股票，价值 143,000 美元，此前在上个季度又收购了 67,153 股。最后，Letko Brosseau &amp; Associates Inc. 在第二季度将其在 Humacyte 的持股比例提高了 85.3%。Letko Brosseau &amp; Associates Inc. 现在持有 45,950 股该公司的股票，价值 96,000 美元，此前在上个季度又收购了 21,150 股。对冲基金和其他机构投资者持有该公司 44.71% 的股票。</p>
</div><h2>Humacyte Stock Down 1.7%</h2>
<div class="lb-trans"><h2>Humacyte 股票下跌 1.7%</h2>
</div><p>Shares of NASDAQ:HUMA opened at $1.13 on Friday. The company's fifty day moving average is $1.06 and its two-hundred day moving average is $1.39. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte, Inc. has a 1-year low of $0.88 and a 1-year high of $3.94. The stock has a market capitalization of $211.62 million, a price-to-earnings ratio of -4.91 and a beta of 1.93.</p>
<div class="lb-trans"><p>NASDAQ:HUMA 的股票在周五开盘时为 1.13 美元。该公司的 50 日移动平均线为 1.06 美元，200 日移动平均线为 1.39 美元。该公司的债务与股本比率为 2.97，速动比率为 0.90，流动比率为 1.62。Humacyte, Inc. 的 1 年最低价为 0.88 美元，1 年最高价为 3.94 美元。该股票的市值为 2.1162 亿美元，市盈率为 -4.91，贝塔值为 1.93。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>HUMA has been the subject of a number of analyst reports. D. Boral Capital restated a &#34;buy&#34; rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday. Benchmark reduced their target price on Humacyte from $11.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, January 21st. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Humacyte in a research report on Monday, December 29th. Wall Street Zen cut shares of Humacyte from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, December 21st. Finally, BTIG Research reiterated a &#34;buy&#34; rating and set a $6.00 price objective on shares of Humacyte in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.14.</p>
<div class="lb-trans"><p>HUMA 曾受到多份分析师报告的关注。D. Boral Capital 在周四的研究报告中重申了对 Humacyte 的 &#34;买入&#34; 评级，并设定了 25.00 美元的目标价。Benchmark 在 1 月 21 日的研究报告中将 Humacyte 的目标价从 11.00 美元下调至 10.00 美元，并对该公司设定了 &#34;买入&#34; 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Humacyte 的 &#34;卖出 (d-)&#34; 评级。Wall Street Zen 在 12 月 21 日的报告中将 Humacyte 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。最后，BTIG Research 在 2 月 9 日的研究报告中重申了对 Humacyte 的 &#34;买入&#34; 评级，并设定了 6.00 美元的目标价。七位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 8.14 美元。</p>
</div><p><strong>Read Our Latest Report on HUMA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 HUMA 的最新报告</strong></p>
</div><h2>Humacyte Profile</h2>
<div class="lb-trans"><h2>Humacyte 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.</p>
<div class="lb-trans"><p>Humacyte, Inc 是一家临床阶段的生物技术公司，专注于开发和制造现成的再生人类无细胞血管 (HAVs)，旨在满足关键的血管通路需求。该公司的专有血管由人类供体细胞工程化而成，然后去细胞化，以创建一种能够与患者自身组织整合的生物相容性支架。Humacyte 的主要业务活动包括 HAVs 的工艺开发、大规模生产和临床评估，适用于终末期肾病、外周动脉疾病和其他血管修复应用。</p>
</div><p>The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.</p>
<div class="lb-trans"><p>该公司的主要产品候选者 HAV 已通过多项临床试验，针对血液透析患者的动静脉通路，显示出耐用性、降低感染率和与重复穿刺的兼容性。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Humacyte</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>Gold $5,000: The 2026 Gold &amp; Silver Summit is LIVE March 4</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>This makes me furious</li>
<li>Elon Musk: This Could Turn $100 into $100,000</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Humacyte</li>
<li>~$1.5T SpaceX IPO：首次公开募股机会</li>
<li>黄金 $5,000:2026 年黄金与白银峰会将于 3 月 4 日直播</li>
<li>家族信托如何帮助保护您的财富</li>
<li>这让我感到愤怒</li>
<li>Elon Musk：这可能将 $100 变成 $100,000</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HUMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 HUMA 吗？</strong> 访问 HoldingsChannel.com 获取 Humacyte, Inc. (NASDAQ:HUMA - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=HUMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Humacyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Humacyte 吗？</h2>
</div><p>Before you consider Humacyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Humacyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Humacyte 并不在名单上。</p>
</div><p>While Humacyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Humacyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

Market Beat

Invesco Nasdaq Biotechnology ETF

Humacyte

CenterBook Partners LP 出售了 Humacyte, Inc. 的 $HUMA 股份